
Opinion|Videos|July 4, 2024
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Author(s)Brad S. Kahl, MD, Tycel Phillips, MD
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
Advertisement
- What is your standard of care (SOC) in this patient population?
- How does this regimen (BTKi+BR) compare in efficacy and safety to your SOC?
Advertisement
Related to this article

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.

The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
2
Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?
3
Cretostimogene Cuts Recurrence Risk in Intermediate-Risk, High-Grade Ta NMIBC
4
Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC
5


